The AI-Bio Supercycle: Industry Outlook and Analysis of Promising Stocks
1. Industry Analysis: Why Now?
The combination of AI and bio has gone beyond simple technology application and entered the stage of 'structural change' that solves the industry's chronic inefficiencies.
💡 Key Synergies and Expected Effects
- A revolution in drug development: Replacing the domain of 'discovery' with AI prediction.
- Popularization of precision medicine: Providing patient-tailored treatment solutions through learning from genomic data.
- Improved diagnostic accuracy: Raising early diagnosis rates through analysis of medical imaging and pathology data.
📊 The Change Seen Through Data (Traditional Methods vs. AI Adoption)
Combining data from global consulting firms and research institutes, AI adoption cuts costs and time by about 50% or more.
| Category | Traditional Method | With AI Adoption (Expected) | Effect |
|---|---|---|---|
| Development period | 10~15 years on average | 6~7 years on average | About 50% shorter (faster capital turnover) |
| Development cost | About 2.3 billion dollars (3 trillion won) | Under 1 billion dollars | Minimized cost of failure and lower barriers to entry |
| Example | Experiments on tens of thousands of compounds needed | Insilico Medicine: From candidate discovery to clinical entry in just 18 months |
2. Market Outlook
- The first year of visible results: 2025~2026 is the period when drug pipelines discovered by AI receive their 'report cards' in the form of clinical results. As expectations turn into results, stock prices will diverge.
- An essential investment destination for Big Tech: As NVIDIA, Google, MS and others point to bio as their next growth engine, astronomical amounts of money are flowing into the AI bio sector.
3. Related Promising Stocks and ETF Portfolio
🇺🇸 U.S. Stocks: The Global Standard
A. Large Caps: Steady Upward Trend
- NVIDIA (NVDA): Operates 'BioNeMo', a generative AI cloud for AI drug development. The infrastructure of the bio industry.
- Eli Lilly (LLY): The No. 1 player in obesity treatments and the pharmaceutical company that collaborates most actively with AI drug development startups.
- Recursion Pharmaceuticals (RXRX): A leading 'AI bio' company that uses AI to develop new drugs. (Has attracted investment from NVIDIA)
- Schrödinger (SDGR): A company that helps drug development with a physics-based software platform.
B. Growth Stocks: High Potential 🚀
- Tempus AI (TEM): A fresh company that listed on the Nasdaq in 2024. It is a 'data company' that analyzes vast clinical and genetic data with AI to suggest optimal treatments to doctors. It has received investment from Google, SoftBank and others, and since AI grows more powerful as data accumulates, its value as a healthcare data platform is very high.
- Twist Bioscience (TWST): For AI to design new drugs, it needs 'data (DNA)' to learn from. This company is a 'bio materials, parts and equipment' company that rapidly manufactures synthetic DNA and supplies it to AI companies. It is a structural beneficiary, as demand for research DNA is bound to explode as AI drug development becomes more active.
🇰🇷 Korean Stocks: Leaders in Niche Markets
Korean companies show competitiveness in diagnostic solutions for specific diseases and in medical devices.
- Lunit (328130): Expanding global sales of its cancer diagnosis solution 'Lunit INSIGHT' and holds AI biomarker technology.
- VUNO (338220): Domestic sales growth of its cardiac arrest prediction device 'VUNO Med-DeepCARS' and pursuing U.S. FDA approval.
- JLK (322510): Specializes in stroke AI solutions and is pursuing listing for U.S. NTAP (New Technology Add-on Payment).
- Seers Technology (458870): AI-based wearable diagnostic devices and remote patient monitoring services.
📈 ETFs: Diversified Investing (Risk Management)
If the volatility of individual stocks is a burden, ETFs are the most reasonable choice.
U.S.-listed
- ARKG (ARK Genomic Revolution ETF): Concentrated investment in the genomic revolution and biotech companies. (High volatility)
- BOTZ (Global X Robotics & AI ETF): A broad AI theme including surgical robots and medical AI.
Korea-listed
- KoAct US Bio Healthcare Active: Actively invests in high-quality U.S. bio companies (Eli Lilly, etc.).
- KOSEF Medical AI: Invests in major domestic medical AI companies such as Lunit and VUNO all at once.